As a player in the growing telehealth sector, Hims & Hers Health ($HIMS) has grown significantly, driving its stock up over ...

Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

Hims & Hers is a fantastic value despite its high on-the-surface P/E ratio and valuation metrics. Click here to read why HIMS ...

Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...

Hims offers a wide variety of Viagra doses and other ED medications. Hims offers other health products and medications for conditions such as hair loss and premature ejaculation. Meetings with ...

Thus, Hims & Hers contends that the FDA’s move doesn’t affect it at all and doesn’t preclude the compounding of GLP-1 drugs. “Products that are not essentially copies can continue to be ...

Subscriptions are needed to obtain prescription products and are created. A representative from Hims states that subscription plans are formatted to ship products out every 30, 90 or 180 days ...

Exploding sales of prescription weight loss medications have catapulted Novo Nordisk (NVO) and Eli Lilly (LLY) to become the ...

Hims & Hers Health (NYSE: HIMS) has built its brand up in recent years by focusing on offering its customers products related to sensitive issues such as hair loss and erectile dysfunction.

Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.